Cyclopeptide RA-V from Rubia yunnanensis restores activity of Adagrasib against colorectal cancer by reducing the expression of Nrf2

Adagrasib (MRTX849), an approved and promising KRAS G12C inhibitor, has shown the promising results for treating patients with advanced non-small cell lung Cancer (NSCLC) or colorectal Cancer (CRC) harboring KRAS-activating mutations. However, emergence of the acquired resistance limits its long-term efficacy and clinical application. Further understanding of the mechanism of the acquired resistance is crucial for developing more new effective therapeutic strategies. Herein, we firstly found a new connection between the acquired resistance to MRTX849 and nuclear factor erythroid 2-related factor 2 (Nrf2). The expression levels of Nrf2 and GLS1 proteins were substantially elevated in different CRC cell lines with the acquired resistance to MRTX849 in comparison with their corresponding parental cell lines. Next, we discovered that RA-V, one of natural Cyclopeptides isolated from the roots of Rubia yunnanensis, could restore the response of resistant CRC cells to MRTX849. The results of molecular mechanisms showed that RA-V suppressed Nrf2 protein through the ubiquitin-proteasome-dependent degradation, leading to the induction of oxidative and ER stress, and DNA damage in CRC cell lines. Consequently, RA-V reverses the resistance to MRTX849 by inhibiting the Nrf2/GLS1 axis, which shows the potential for further developing into one of novel Adjuvant therapies of MRTX849.

Bafilomycin A1 (PubChem CID: 6436223); CHX (PubChem CID: 6197); Colorectal cancer; DAPI (PubChem CID: 2954); DMSO (PubChem CID: 679); DNA damage; Leupeptin (PubChem CID: 72429); MG132 (PubChem CID: 462382); MRTX849 (PubChem CID: 138611145); MRTX849 resistance; MTT (PubChem CID: 64965); Natural cyclopeptide RA-V; Nrf2/GLS1 axis; Oxidative and ER stress; RA-V (PubChem CID: 13361282); tBHQ (PubChem CID: 16043).